Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.81 |
| ▸ | NPC1 | O15118 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.71 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607164 | 1.00 | MAPT (1.00) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL3215707 | 0.92 | TNFRSF1A (1.00) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL3215700 | 0.92 | TNFRSF1A (1.00) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL30383266 | 0.92 | TNFRSF1A (1.00) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL30674925 | 0.92 | TNFRSF1A (1.00) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL19182870 | 0.89 | LMNA (1.00) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL19182869 | 0.89 | LMNA (1.00) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL29600833 | 0.88 | TNFRSF1A (0.86) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL7180313 | 0.88 | TNFRSF1A (0.86) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 | |
| SCHEMBL7180309 | 0.88 | TNFRSF1A (0.86) | MAPTLMNAHPGDTNFRSF1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2720712-A2 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | Halozyme, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| WO-2012174478-A9 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME, INC. (US) | 2013-05-30 | — | — | WO | claimed |
| WO-2012174478-A2 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME, INC. (US) | 2012-12-20 | — | — | WO | claimed |
| EP-1781305-A2 | COMPOSITIONS AND METHODS USING HYALURONIC ACID AND HYALURONIDASE INHIBITORS | ANGIOTECH INTERNATIONAL AG (CH) | 2007-05-09 | — | — | EP | claimed |
| WO-2006020994-A2 | COMPOSITIONS AND METHODS USING HYALURONIC ACID AND HYLURONIDASE INHIBITORS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-02-23 | — | — | WO | claimed |
| US-9993529-B2 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2720712-B1 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2720713-A2 | CONTINUOUS SUBCUTANEOUS INSULIN INFUSION METHODS WITH A HYALURONAN DEGRADING ENZYME | Halozyme, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2720712-A2 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | Halozyme, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174478-A9 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20130022592-A1 | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme | HALOZYME THERAPEUTICS, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | HALOZYME THERAPEUTICS, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| WO-2012174478-A2 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174480-A2 | CONTINUOUS SUBCUTANEOUS INSULIN INFUSION METHODS WITH A HYALURONAN DEGRADING ENZYME | HALOZYME, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| EP-1781305-A2 | COMPOSITIONS AND METHODS USING HYALURONIC ACID AND HYALURONIDASE INHIBITORS | ANGIOTECH INTERNATIONAL AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20060040894-A1 | Compositions and methods using hyaluronic acid | ANGIOTECH INTERNATIONAL AG (CH) | 2006-02-23 | — | — | US | disclosed |
| WO-2006020994-A2 | COMPOSITIONS AND METHODS USING HYALURONIC ACID AND HYLURONIDASE INHIBITORS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | IDE, MMP20, IDUA | MAPT 3776/4885LMNA 2926/4885HPGD 387/4885 |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | IDE, IDUA, MMP20 | MAPT 3550/4885LMNA 2736/4885HPGD 369/4885 |
| US-20060040894-A1 | Compositions and methods using hyaluronic acid | CD44, MMP13, MMP1 | MAPT 4556/4885LMNA 1184/4885HPGD 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.